406 related articles for article (PubMed ID: 16415311)
1. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of tolterodine for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Agarwal A; Raza M; Singhal V; Dhiraaj S; Kapoor R; Srivastava A; Gupta D; Singh PK; Pandey CK; Singh U
Anesth Analg; 2005 Oct; 101(4):1065-1067. PubMed ID: 16192522
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.
Armstrong RB; Luber KM; Peters KM
Int Urol Nephrol; 2005; 37(2):247-52. PubMed ID: 16142551
[TBL] [Abstract][Full Text] [Related]
5. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
Abrams P; Freeman R; Anderström C; Mattiasson A
Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
[TBL] [Abstract][Full Text] [Related]
6. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
Malone-Lee J; Shaffu B; Anand C; Powell C
J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
Appell RA
Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S
Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
Homma Y; Paick JS; Lee JG; Kawabe K;
BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
[TBL] [Abstract][Full Text] [Related]
14. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
Homma Y; Kawabe K
World J Urol; 2004 Oct; 22(4):251-6. PubMed ID: 15455256
[TBL] [Abstract][Full Text] [Related]
16. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
Sussman D; Garely A
Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
[TBL] [Abstract][Full Text] [Related]
17. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
Jafarabadi M; Ghanbari Z; Hashemi S; Nemati M; Haghollahi F; Azimi Nekoo E
Acta Med Iran; 2015; 53(2):125-8. PubMed ID: 25725183
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
[TBL] [Abstract][Full Text] [Related]
19. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
Altan-Yaycioglu R; Yaycioglu O; Aydin Akova Y; Guvel S; Ozkardes H
Br J Clin Pharmacol; 2005 May; 59(5):588-92. PubMed ID: 15842558
[TBL] [Abstract][Full Text] [Related]
20. Clinical experiences with tolterodine.
Nilvebrant L
Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
